GridAI Technologies is a pre-revenue, early-stage company operating two unrelated businesses. Its primary focus is an energy orchestration and optimization software platform, developed through its Grid AI Corp. subsidiary, targeting AI data centers and other large energy users. The platform integrates distributed energy resources — including battery storage, on-site generation, and grid connections — to reduce power costs and improve reliability for data center operators. Core features include real-time monitoring, a digital twin site model, load forecasting, and a co-optimization engine that participates in wholesale energy markets. GridAI targets enterprise and government data center operators, hyperscalers, and energy infrastructure developers, primarily in North America and Australia. The planned business model combines base platform fees with performance-based fees tied to energy cost savings. GridAI also retains a legacy clinical-stage drug program, Adrulipase, a recombinant lipase enzyme for treating exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients. Neither business has generated material revenue. The data center platform has not been commercially deployed, no definitive commercial agreements have been signed, and the Adrulipase program ran no clinical trials in 2025. The company has undergone repeated rebranding and strategic pivots since its founding in 2014, operates with only 2 full-time parent-level employees, and has faced ongoing Nasdaq compliance issues.